JP2024543505A - 癌の治療方法 - Google Patents

癌の治療方法 Download PDF

Info

Publication number
JP2024543505A
JP2024543505A JP2024529127A JP2024529127A JP2024543505A JP 2024543505 A JP2024543505 A JP 2024543505A JP 2024529127 A JP2024529127 A JP 2024529127A JP 2024529127 A JP2024529127 A JP 2024529127A JP 2024543505 A JP2024543505 A JP 2024543505A
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
patients
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543505A5 (https=
Inventor
ワトソン,ショーン
スメサースト,ドミニク
ウパディアヤ,プニト
ウィティ,デイビッド
マクドネル,ケビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2024543505A publication Critical patent/JP2024543505A/ja
Publication of JP2024543505A5 publication Critical patent/JP2024543505A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024529127A 2021-11-16 2022-11-16 癌の治療方法 Pending JP2024543505A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163264132P 2021-11-16 2021-11-16
US63/264,132 2021-11-16
PCT/GB2022/052903 WO2023089308A1 (en) 2021-11-16 2022-11-16 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2024543505A true JP2024543505A (ja) 2024-11-21
JP2024543505A5 JP2024543505A5 (https=) 2025-11-26

Family

ID=84535807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529127A Pending JP2024543505A (ja) 2021-11-16 2022-11-16 癌の治療方法

Country Status (9)

Country Link
EP (1) EP4433025A1 (https=)
JP (1) JP2024543505A (https=)
KR (1) KR20240100420A (https=)
CN (1) CN118475345A (https=)
AU (1) AU2022390670A1 (https=)
CA (1) CA3237681A1 (https=)
IL (1) IL312680A (https=)
MX (1) MX2024005855A (https=)
WO (1) WO2023089308A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
WO2025125648A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide complex for use in treating cancer
WO2025125652A1 (en) * 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物

Also Published As

Publication number Publication date
KR20240100420A (ko) 2024-07-01
WO2023089308A1 (en) 2023-05-25
MX2024005855A (es) 2024-05-28
CA3237681A1 (en) 2023-05-25
EP4433025A1 (en) 2024-09-25
AU2022390670A1 (en) 2024-05-23
CN118475345A (zh) 2024-08-09
IL312680A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP2024543505A (ja) 癌の治療方法
AU2020392890A1 (en) Bicyclic peptide ligands specific for EphA2 and uses thereof
AU2021276616A1 (en) Bicyclic peptide ligands specific for Nectin-4 and uses thereof
JP2024545125A (ja) Stat3分解剤およびその使用
KR20250056270A (ko) 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법
AU2024279019A1 (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
WO2024246547A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024248859A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
KR20250058748A (ko) 중간엽 상피 전이 인자 (met)-표적 제제를 이용한 비-소 세포성 폐암 치료 방법
WO2025125648A1 (en) Bicyclic peptide complex for use in treating cancer
EP4427751A1 (en) Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma
WO2024248860A1 (en) Bicyclic peptide ligands specific for epha2 and uses thereof
WO2025056907A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
EA047123B1 (ru) Бициклические пептидные лиганды, специфические для нектина-4, и их применение
WO2025260061A1 (en) Compositions and methods for cancer therapy
WO2025125809A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
KR20250069903A (ko) 암 치료를 위한 B-Raf 저해제와 항-EGFR 항체의 조합물
WO2025125652A1 (en) Combination therapy for use in treating cancer
WO2025117875A1 (en) Compounds for treating solid tumors having activating fgfr2 gene alterations
EP4598520A1 (en) Methods of treating estrogen receptor-mediated disorders
CA3269490A1 (en) Methods of treating estrogen receptor-mediated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114